Brought to you by the American Public Health Association and the National Academy of Medicine, this webinar series ran from March 2020 to January 2022 exploring the state of the science surrounding the current outbreak of COVID-19 in the United States and globally, with a focus on the emerging evidence on how to best mitigate its impact. Hear from trusted experts in such fields as public health, infectious disease, risk communication, and crisis standards of care.
The latest COVID-19 Conversations webinar gave insight into what we have learned from the omicron variant, and how that knowledge, as well as an evolving understanding of vaccine efficacy, emerging therapeutics, and public health guidance can help us move toward the new normal.
Our expert panel:
- Megan Ranney, Brown University (Moderator)
- Jennifer Nuzzo, Johns Hopkins Center for Health Security
- Larry Corey, Fred Hutchison Cancer Research Center
- Roy (Trip) Gulick, Weill Cornell Medicine
- Georges Benjamin, APHA
The 21st COVID-19 Conversations webinar provided an update on the current state of COVID-19, focusing specifically on the delta variant, implications for children under the age of 12, what the rise of this highly infectious variant means for vaccinated and unvaccinated adults and adolescents, and what it will take to move past this surge and end the pandemic.
Our expert panel:
- Esther Krofah (Moderator), FasterCures and the Milken Institute Center for Public Health
- George Rutherford, University of California, San Francisco
- Charlene Wong, Duke University School of Medicine
- Peter Hotez, Baylor College of Medicine
- Mitchell Katz, NYC Health + Hospitals
MORE ABOUT THE WEBINAR SERIES
The webinar series draws from and complements existing advisory activities underway at APHA and the National Academies, including the Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats, which was convened for the purpose of advising the White House and federal agencies on the U.S. response to COVID-19.
The series rapidly and regularly provides trustworthy scientific analysis of the latest COVID-19 developments for the benefit of policymakers, public health and health care officials, and the general public.
The series is exploring the scientific basis for guidance issued by government, health and public health organizations, and industry, as well as answering questions that are top of mind for its audiences.
Questions? Contact us.